铁亡的药理抑制减轻了实验性的腹腔大动脉动脉瘤形成
Jonathan R Krebs1, Paolo Bellotti1, Walker Ueland1
1Department of Surgery (J.R.K., P.B., W.U., J.A.C.V., D.J.M.K., S.S., G.S., J.B.H., A.A., M.S., G.C., A.K.S., G.R.U.), University of Florida, Gainesville.
Arteriosclerosis, thrombosis, and vascular biology
|October 2, 2025
概括
这项研究表明,抑制巨细胞中细胞死亡的一种形式铁亡,可以减少腹腔大动脉动脉瘤 (AAA) 的发展和相关的血管炎症.
科学领域:
- 心血管生物学 心血管生物学
- 细胞死亡机制 细胞死亡机制
- 血管改造是指进行血管改造.
背景情况:
- 腹腔大动脉动脉瘤 (AAA) 的发病包括血管炎症,血栓形成和细胞死亡,导致大动脉重塑.
- 铁,一种铁介导的细胞死亡,在巨细胞驱动的大动脉炎症和AAA形成的重塑中发挥作用.
研究的目的:
- 在AAA形成过程中研究铁死在巨细胞中的作用.
- 为了确定抑制铁亡是否可以减轻AAA的发展和相关的病理变化.
主要方法:
- 人类AAA组织的单细胞RNA测序.
- 在野生型小鼠中使用弹性酶模型诱导AAA,有或没有liproxstatin-1 (ferroptosis抑制剂).
- 对大动脉直径,细胞因子表达,组织学,铁亡标志物和脂质样本的分析;对巨细胞和平滑肌肉细胞交叉的体外研究.
主要成果:
- 人类AAA组织中的巨细胞中与铁亡相关的基因的显著差异.
- 在小鼠中,Liproxstatin-1治疗减弱了大动脉直径,炎症,免疫细胞透和弹性纤维破坏.
- 脂质组分析显示AAA组织中的胺物质和完整的脂质物种水平发生了变化.
- 实验室研究表明,利普罗克斯塔丁-1减轻了巨细胞铁亡,MMP9表达,并通过MMP2与光滑肌肉细胞交叉交叉.
结论:
- 通过liproxstatin-1对铁亡的药理抑制可以减轻对巨细胞依赖的铁亡.
- 这种抑制有助于减少大动脉炎症和AAA形成的重塑.
相关概念视频
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...